PeptiMimesis is a leading brand specializing in the design, discovery, and early development of transmembrane therapeutic peptides. Our innovative approach enables us to identify peptidomimetic candidates that interfere with the hetero- and/or the homodimerization of target receptors, providing breakthrough solutions for various medical conditions. With a focus on oncology and immuno-oncology, PeptiMimesis is developing a robust pipeline of therapeutic peptides that target key receptors in these fields.

We are also open to collaborating with pharmaceutical partners who share our interest in specific receptors. Our recent achievements include securing €1. 2m ($1.

4m) from Cap Innov’Est to launch our groundbreaking technology platform for identifying next-generation therapeutic peptides. PeptiMimesis continues to receive support and funding, with a particular emphasis on advancing our transmembrane peptide pipeline for HER2 positive breast cancer–derived brain metastasis. For inquiries and further information, please contact us at contact@peptimimesis.

com. We are headquartered at 850 Boulevard Sébastien Brant, Illkirch, France